{"DataElement":{"publicId":"12103260","version":"1","preferredName":"Corticosteroid Administered Agent Name","preferredDefinition":"The name of the corticosteroid that was administered.","longName":"CORTICO_ADMIN_NM","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"3431181","version":"1","preferredName":"Corticosteroid Administered","preferredDefinition":"The administration of corticosteroids to the patient.","longName":"CORTICO_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2452713","version":"1","preferredName":"Corticosteroid","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","longName":"C2322","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D052842-7E94-4FD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCCBC2C0-E3D0-2D9B-E040-BB89AD436F5F","latestVersionIndicator":"Yes","beginDate":"2012-04-03","endDate":null,"createdBy":"EGANK","dateCreated":"2012-04-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7348856","version":"1","preferredName":"Agent Name","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known.","longName":"7348856v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"PD-325901","valueDescription":"MEK Inhibitor PD0325901","ValueMeaning":{"publicId":"7348903","version":"1","preferredName":"MEK Inhibitor PD0325901","longName":"7348903","preferredDefinition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mirdametinib","conceptCode":"C52195","definition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C6C6E1-3734-5FD0-E053-4EBD850AF325","latestVersionIndicator":"Yes","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C6C6E1-374D-5FD0-E053-4EBD850AF325","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"Pregabalin","valueDescription":"Pregabalin","ValueMeaning":{"publicId":"3835527","version":"1","preferredName":"Pregabalin","longName":"3835527","preferredDefinition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregabalin","conceptCode":"C64625","definition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-9334-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D460-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Gabapentin","valueDescription":"Gabapentin","ValueMeaning":{"publicId":"2576881","version":"1","preferredName":"Gabapentin","longName":"2576881","preferredDefinition":"A substance that is being studied as a treatment for relieving hot flashes in women with breast cancer.  It belongs to the family of drugs called anticonvulsants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gabapentin","conceptCode":"C1108","definition":"A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D46A-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Nortriptyline","valueDescription":"Nortriptyline","ValueMeaning":{"publicId":"7460881","version":"1","preferredName":"Nortriptyline","longName":"7460881","preferredDefinition":"A tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nortriptyline","conceptCode":"C62060","definition":"A tricyclic antidepressant agent used for short-term treatment of various forms of depression. Nortriptyline blocks the norepinephrine presynaptic receptors, thereby blocking the reuptake of this neurotransmitter and raising the concentration in the synaptic cleft in the CNS. Nortriptyline also binds to alpha-adrenergic, histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces a downregulation of adrenergic receptors due to the increased stimulation of these receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D477-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D490-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Amitriptyline","valueDescription":"Amitriptyline","ValueMeaning":{"publicId":"2576001","version":"1","preferredName":"Amitriptyline","longName":"2576001v1.00","preferredDefinition":"A derivative of dibenzocycloheptadiene and a tricyclic antidepressant. Amitriptyline inhibits the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. Due to constant stimulation to these receptors, amitriptyline may produce a downregulation of adrenergic and serotonin receptors, which may contribute to the antidepressant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amitriptyline","conceptCode":"C62005","definition":"A derivative of dibenzocycloheptadiene and a tricyclic antidepressant. Amitriptyline inhibits the re-uptake of norepinephrine and serotonin by the presynaptic neuronal membrane in the central nervous system (CNS), thereby increasing the synaptic concentration of norepinephrine and serotonin. Due to constant stimulation to these receptors, amitriptyline may produce a downregulation of adrenergic and serotonin receptors, which may contribute to the antidepressant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5EE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D49A-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Escitalopram","valueDescription":"Escitalopram","ValueMeaning":{"publicId":"7460883","version":"1","preferredName":"Escitalopram","longName":"7460883","preferredDefinition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Escitalopram","conceptCode":"C61754","definition":"The active S-stereoisomer of the selective serotonin reuptake inhibitor (SSRI) citalopram with antidepressant, anti-obsessive-compulsive and antibulimic properties. Escitalopram inhibits the reuptake of the neurotransmitter serotonin (5-HT) at the serotonin reuptake pump of the neuronal membrane of the presynaptic cell, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on 5HT1A autoreceptors. Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein but also to a secondary lower-affinity allosteric site that is considered to stabilize and prolong drug binding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D4A7-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D4C0-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Sertraline","valueDescription":"Sertraline","ValueMeaning":{"publicId":"7460884","version":"1","preferredName":"Sertraline","longName":"7460884","preferredDefinition":"A drug used to treat depression. It is a type of selective serotonin reuptake inhibitor (SSRI).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sertraline","conceptCode":"C61939","definition":"A drug used to treat depression. It is a type of selective serotonin reuptake inhibitor (SSRI).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D4CC-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D4E5-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Fluoxetine","valueDescription":"Fluoxetine","ValueMeaning":{"publicId":"7460885","version":"1","preferredName":"Fluoxetine","longName":"7460885","preferredDefinition":"A drug used to treat depression.  It belongs to the family of drugs called antidepressants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluoxetine","conceptCode":"C506","definition":"A diphenhydramine derivative and selective serotonin reuptake inhibitor with antidepressant, anti-anxiety, antiobsessional and antibulimic activity and with potential immunomodulating activity. Upon administration, fluoxetine binds to the presynaptic serotonin (5-HT) receptor resulting in negative allosteric modulation of the receptor complex, thereby blocking recycling of serotonin by the presynaptic receptor. Inhibition of serotonin reuptake by fluoxetine enhances serotonergic function through serotonin accumulation in the synaptic space, resulting in long-term desensitization and downregulation of 5-HT receptors, preventing 5-HT-mediated signaling and leading to antidepressant, anti-anxiety, antiobsessional and antibulimic effects. In addition, fluoxetine may inhibit the expression of pro-inflammatory cytokines, including interleukin-6 (IL-6). This may prevent IL-6-mediated inflammation and cytokine storm.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D4F1-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D50A-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Citalopram","valueDescription":"Citalopram","ValueMeaning":{"publicId":"7460886","version":"1","preferredName":"Citalopram","longName":"7460886","preferredDefinition":"A bicyclic phthalene derivative and selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activities. Citalopram selectively inhibits the neuronal reuptake of the neurotransmitter serotonin (5-HT) in presynaptic cells in the central nervous system, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on its receptors. Increased serotonergic neurotransmission results in antidepressive and anxiolytic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citalopram","conceptCode":"C61680","definition":"A bicyclic phthalene derivative and selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activities. Citalopram selectively inhibits the neuronal reuptake of the neurotransmitter serotonin (5-HT) in presynaptic cells in the central nervous system, thereby increasing levels of 5-HT within the synaptic cleft and enhancing the actions of serotonin on its receptors. Increased serotonergic neurotransmission results in antidepressive and anxiolytic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D516-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D52F-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Lacosamide","valueDescription":"Lacosamide","ValueMeaning":{"publicId":"3232363","version":"1","preferredName":"Lacosamide","longName":"3232363v1.00","preferredDefinition":"A functionalized amino acid compound specifically synthesized as an anticonvulsive drug to use as add-on therapy for partial-onset seizures with antinociceptive and neuroprotective activities. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, thereby stabilizing hyperexcitabe neuronal membranes. Furthermore, this agent binds to collapsin response mediator protein 2 (CRMP2; DPYSL2), a cytosolic phosphoprotein expressed in most tissues. In the nervous system, CRMP2 acts as a mediator of growth cone collapse as well as modifies axon number, length, and neuronal polarity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lacosamide","conceptCode":"C83859","definition":"A functionalized amino acid compound specifically synthesized as an anticonvulsive drug to use as add-on therapy for partial-onset seizures with antinociceptive and neuroprotective activities. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, thereby stabilizing hyperexcitabe neuronal membranes. Furthermore, this agent binds to collapsin response mediator protein 2 (CRMP2; DPYSL2), a cytosolic phosphoprotein expressed in most tissues. In the nervous system, CRMP2 acts as a mediator of growth cone collapse as well as modifies axon number, length, and neuronal polarity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1F2CCF0-7030-F4FA-E040-BB89AD434EDB","latestVersionIndicator":"Yes","beginDate":"2011-04-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-27","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D539-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Lamotrigine","valueDescription":"Lamotrigine","ValueMeaning":{"publicId":"2578216","version":"1","preferredName":"Lamotrigine","longName":"2578216","preferredDefinition":"A synthetic phenyltriazine with antiepileptic and analgesic properties.  Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lamotrigine","conceptCode":"C38703","definition":"A synthetic phenyltriazine with antiepileptic and analgesic properties.  Lamotrigine enhances the action of gamma-aminobutyric acid, an inhibitory neurotransmitter, which may result in a reduction of pain-related transmission of signals along nerve fibers. This agent may also inhibit voltage-gated sodium channels, suppress glutamate release, and inhibit serotonin reuptake. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE95-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D543-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Valproic acid","valueDescription":"Valproic Acid","ValueMeaning":{"publicId":"7460887","version":"1","preferredName":"Valproic Acid","longName":"7460887","preferredDefinition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valproic Acid","conceptCode":"C29536","definition":"A synthetic derivative of propylpentanoic acid with antiepileptic properties and potential antineoplastic and antiangiogenesis activities.  In epilepsy, valproic acid appears to act by increasing the concentration of gamma-aminobutyric acid (GABA) in the brain. This agent's antitumor and antiangiogenesis activities may be related to the inhibition of histone deacetylases and nitric oxide synthase, which results in the inhibition of nitric oxide synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D54F-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D568-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C85ACF-CF1E-10C3-E053-4EBD850A23EA","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"Trametinib","valueDescription":"Trametinib","ValueMeaning":{"publicId":"3523220","version":"1","preferredName":"Trametinib","longName":"3523220","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-4590-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C869AD-2BF6-5FCE-E053-4EBD850A1E05","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"Cobimetinib","valueDescription":"MEK inhibitor GDC-0973","ValueMeaning":{"publicId":"3653958","version":"1","preferredName":"MEK inhibitor GDC-0973","longName":"3653958","preferredDefinition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cobimetinib","conceptCode":"C68923","definition":"An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E1EFE4-45EB-52B6-E040-BB89AD431E3D","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C869AD-2C0A-5FCE-E053-4EBD850A1E05","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"Selumetinib","valueDescription":"Selumetinib","ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C869AD-2C00-5FCE-E053-4EBD850A1E05","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"Binimetinib","valueDescription":"Binimetinib","ValueMeaning":{"publicId":"4828187","version":"1","preferredName":"Binimetinib","longName":"4828187","preferredDefinition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Binimetinib","conceptCode":"C84865","definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49B7-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C869AD-2C14-5FCE-E053-4EBD850A1E05","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"ONEDATA","dateModified":"2020-07-06","deletedIndicator":"No"},{"value":"BRAF Inhibitor","valueDescription":"BRAF Inhibitor","ValueMeaning":{"publicId":"6678120","version":"1","preferredName":"BRAF Inhibitor","longName":"6678120","preferredDefinition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BRAF Inhibitor","conceptCode":"C155322","definition":"Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"848B0602-EFA5-6BF2-E053-F662850A9E58","latestVersionIndicator":"Yes","beginDate":"2019-03-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-03-20","modifiedBy":"ONEDATA","dateModified":"2019-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145B5DF-5F1A-2D9E-E053-4EBD850AE279","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"MEK Inhibitor","valueDescription":"Mitogen-Activated Protein Kinase Kinase Inhibitor","ValueMeaning":{"publicId":"3218952","version":"1","preferredName":"Mitogen-Activated Protein Kinase Kinase Inhibitor","longName":"3218952","preferredDefinition":"Substances that inhibit Mitogen-Activated Protein Kinase Kinase (MEK), enzymes involved with signal transduction, and may inhibit cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitogen-Activated Protein Kinase Kinase Inhibitor","conceptCode":"C69145","definition":"Any substance that inhibits mitogen-activated protein kinase kinase (MEK), an enzyme that catalyzes the addition of a phosphate group to a mitogen-activated protein kinase. Inhibition of mitogen-activated protein kinase kinase results in the inhibition of cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9FCB1285-74AB-D8CA-E040-BB89AD433739","latestVersionIndicator":"Yes","beginDate":"2011-03-31","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145B5DF-5F24-2D9E-E053-4EBD850AE279","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145B5DF-5F2E-2D9E-E053-4EBD850AE279","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Vinblastine","valueDescription":"Vinblastine","ValueMeaning":{"publicId":"3380287","version":"1","preferredName":"Vinblastine","longName":"3380287","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A492-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145B5DF-5F38-2D9E-E053-4EBD850AE279","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145B5DF-5F42-2D9E-E053-4EBD850AE279","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"CAR T-Cell","valueDescription":"Chimeric Antigen Receptor T-Cell Therapy","ValueMeaning":{"publicId":"7331413","version":"1","preferredName":"Chimeric Antigen Receptor T-Cell Therapy","longName":"7331413","preferredDefinition":"A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. Chimeric antigen receptor T-cell therapy is being studied in the treatment of some types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chimeric Antigen Receptor T-Cell Therapy","conceptCode":"C126102","definition":"Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-396E-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2023-02-01","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B012BF19-36BB-7D51-E053-4EBD850A2EEE","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Inotuzumab Ozogamicin","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B012BF19-36C5-7D51-E053-4EBD850A2EEE","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B012BF19-36CF-7D51-E053-4EBD850A2EEE","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0134586-E858-205E-E053-4EBD850A4834","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Steroid therapy","valueDescription":"Steroid Therapy","ValueMeaning":{"publicId":"7433982","version":"1","preferredName":"Steroid Therapy","longName":"7433982","preferredDefinition":"Treatment with corticosteroid drugs to reduce swelling, pain, and other symptoms of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Steroid Therapy","conceptCode":"C15370","definition":"The use of exogenous steroids for the treatment of any disease or disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0134586-E862-205E-E053-4EBD850A4834","latestVersionIndicator":"Yes","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":null,"administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0134586-E87B-205E-E053-4EBD850A4834","beginDate":"2020-09-24","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-09-24","modifiedBy":"ONEDATA","dateModified":"2020-09-24","deletedIndicator":"No"},{"value":"Clobazam","valueDescription":"Clobazam","ValueMeaning":{"publicId":"3680999","version":"1","preferredName":"Clobazam","longName":"3680999v1.00","preferredDefinition":"A 1,5-benzodiazepine and partial gamma-aminobutyric acid (GABA) receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. Clobazam binds to a specific site, distinct from the inhibitory neurotransmitter GABA binding site, on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the opening of chloride-channels. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clobazam","conceptCode":"C81615","definition":"A 1,5-benzodiazepine and partial gamma-aminobutyric acid (GABA) receptor agonist, with anxiolytic, sedative, and anticonvulsant activities. Clobazam binds to a specific site, distinct from the inhibitory neurotransmitter GABA binding site, on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the central nervous system (CNS). This binding causes an allosteric modification of the receptor and enhances the affinity of GABA to the receptor leading to an increase in the opening of chloride-channels. This leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential and a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D510745F-508C-1FFA-E040-BB89AD4306DC","latestVersionIndicator":"Yes","beginDate":"2013-02-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D572-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Levetiracetam","valueDescription":"Levetiracetam","ValueMeaning":{"publicId":"2578221","version":"1","preferredName":"Levetiracetam","longName":"2578221","preferredDefinition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levetiracetam","conceptCode":"C47581","definition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D57C-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Topiramate","valueDescription":"Topiramate","ValueMeaning":{"publicId":"7460889","version":"1","preferredName":"Topiramate","longName":"7460889","preferredDefinition":"A sulfamate-substituted monosaccharide with anticonvulsant property. Although the mechanism of action has not been fully elucidated, topiramate antagonizes kainate/AMPA subtype of the glutamate receptors, which are ligand-activated cation channels that mediate the fast component of excitatory postsynaptic currents in neurons of the central nervous system. This antagonistic action results in stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses, thereby impedes seizure occurrences. In addition, this agent augments gamma-aminobenzoic acid (GABA) activity and thereby attenuating GABAnergic inhibitory transmission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topiramate","conceptCode":"C47764","definition":"A sulfamate-substituted monosaccharide with anticonvulsant property. Although the mechanism of action has not been fully elucidated, topiramate antagonizes kainate/AMPA subtype of the glutamate receptors, which are ligand-activated cation channels that mediate the fast component of excitatory postsynaptic currents in neurons of the central nervous system. This antagonistic action results in stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and decreasing propagation of synaptic impulses, thereby impedes seizure occurrences. In addition, this agent augments gamma-aminobenzoic acid (GABA) activity and thereby attenuating GABAnergic inhibitory transmission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D589-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5A2-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Methadone","valueDescription":"Methadone","ValueMeaning":{"publicId":"2576437","version":"1","preferredName":"Methadone","longName":"2576437v1.00","preferredDefinition":"A synthetic opioid with analgesic activity. Methadone mimics the actions of endogenous peptides at CNS opioid receptors, primarily on the mu-receptor and has actions similar to those of morphine and morphine-like agents. The characteristic morphine-like effects include analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. However, the detoxification symptoms between morphine-like agents and methadone differ in that the onset of methadone's withdrawal symptoms is slower, the course is more prolonged and the symptoms are less severe.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methadone","conceptCode":"C62044","definition":"A synthetic opioid with analgesic activity. Methadone mimics the actions of endogenous peptides at CNS opioid receptors, primarily on the mu-receptor and has actions similar to those of morphine and morphine-like agents. The characteristic morphine-like effects include analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. However, the detoxification symptoms between morphine-like agents and methadone differ in that the onset of methadone's withdrawal symptoms is slower, the course is more prolonged and the symptoms are less severe.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7A2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5AC-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Meperidine","valueDescription":"Meperidine","ValueMeaning":{"publicId":"5211116","version":"1","preferredName":"Meperidine","longName":"5211116","preferredDefinition":"A synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors, thereby producing the characteristic morphine-like effects on the mu-opioid receptor, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meperidine","conceptCode":"C71632","definition":"A synthetic piperidine ester with opioid analgesic activity. Meperidine mimics the actions of endogenous neuropeptides via opioid receptors, thereby producing the characteristic morphine-like effects on the mu-opioid receptor, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC947D3-EE49-E06C-E050-BB89AD4321A6","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5B6-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Percocet","valueDescription":"Oxycodone/Acetaminophen","ValueMeaning":{"publicId":"6287980","version":"1","preferredName":"Oxycodone/Acetaminophen","longName":"6287980","preferredDefinition":"A combination preparation of the analgesic and antipyretic acetaminophen and the semisynthetic opioid agonist oxycodone with analgesic and antitussive properties. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxycodone/Acetaminophen","conceptCode":"C29311","definition":"A combination preparation of the analgesic and antipyretic acetaminophen and the semisynthetic opioid agonist oxycodone with analgesic and antitussive properties. Acetaminophen exerts its analgesic activity by inhibiting prostaglandin synthesis, while oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C430E2D-FA59-6D57-E053-F662850A02D6","latestVersionIndicator":"Yes","beginDate":"2018-05-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-15","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5C0-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Tramadol","valueDescription":"Tramadol","ValueMeaning":{"publicId":"3380229","version":"1","preferredName":"Tramadol","longName":"3380229","preferredDefinition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tramadol","conceptCode":"C29507","definition":"A synthetic codeine analogue, Tramadol has central analgesic properties with effects similar to opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic analgesic for severe pain, it can be addictive and weakly inhibits norepinephrine and serotonin reuptake. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-15B8-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5CA-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Hydrocodone","valueDescription":"Hydrocodone","ValueMeaning":{"publicId":"2576432","version":"1","preferredName":"Hydrocodone","longName":"2576432v1.00","preferredDefinition":"A semisynthetic hydrogenated codeine derivative and opioid agonist with analgesic and antitussive effects. Hydrocodone primarily binds to and activates the mu-opioid receptor in the central nervous system (CNS). This leads to analgesia, euphoria, respiratory depression, miosis, decreased gastrointestinal motility, cough suppression and physical dependence. Hydrocodone is converted to hydromorphone by the cytochrome P450 enzyme CYP2D6.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrocodone","conceptCode":"C62033","definition":"A semisynthetic hydrogenated codeine derivative and opioid agonist with analgesic and antitussive effects. Hydrocodone primarily binds to and activates the mu-opioid receptor in the central nervous system (CNS). This leads to analgesia, euphoria, respiratory depression, miosis, decreased gastrointestinal motility, cough suppression and physical dependence. Hydrocodone is converted to hydromorphone by the cytochrome P450 enzyme CYP2D6.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F79D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"KUMMEROA","dateModified":"2023-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5D4-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Codeine","valueDescription":"Codeine Phosphate","ValueMeaning":{"publicId":"2576059","version":"1","preferredName":"Codeine Phosphate","longName":"2576059","preferredDefinition":"An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Codeine","conceptCode":"C383","definition":"A naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activities. Codeine mimics the actions of endogenous opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of mu-subtype opioid receptors results in a decrease in the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline; in addition, the codeine metabolite morphine induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability. Stimulation of gut mu-subtype opioid receptors results in a reduction in intestinal motility and delayed intestinal transit times. Antitussive activity is mediated through codeine's action on the cough center in the medulla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F628-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5DE-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Oxycodone","valueDescription":"Oxycodone","ValueMeaning":{"publicId":"4804377","version":"1","preferredName":"Oxycodone","longName":"4804377","preferredDefinition":"A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxycodone","conceptCode":"C29309","definition":"A semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"14D48A7B-0EBA-07D2-E050-BB89AD436B74","latestVersionIndicator":"Yes","beginDate":"2015-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5E8-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Fentanyl","valueDescription":"Fentanyl","ValueMeaning":{"publicId":"2576850","version":"1","preferredName":"Fentanyl","longName":"2576850","preferredDefinition":"A narcotic opioid drug that is used in the treatment of pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fentanyl","conceptCode":"C494","definition":"A synthetic, lipophilic phenylpiperidine opioid agonist with analgesic and anesthetic properties. Fentanyl selectively binds to and activates the mu-receptor in the central nervous system (CNS) thereby mimicking the effects of endogenous opiates. Activation of the mu-subtype opioid receptor stimulates the exchange of GTP for GDP on the G-protein complex and subsequently inhibits adenylate cyclase. This causes a decrease in intracellular cAMP which inhibits cAMP-mediated calcium influx into the cell via the calcium channels and thereby results in hyperpolarization and reduced neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F93F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5F2-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Morphine","valueDescription":"Morphine","ValueMeaning":{"publicId":"5211114","version":"1","preferredName":"Morphine","longName":"5211114","preferredDefinition":"An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent exhibits widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphine","conceptCode":"C62051","definition":"An opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically. Morphine binds to and activates specific opiate receptors (delta, mu and kappa), each of which are involved in controlling different brain functions. In the central nervous and gastrointestinal systems, this agent exhibits widespread effects including analgesia, anxiolysis, euphoria, sedation, respiratory depression, and gastrointestinal system smooth muscle contraction. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC947D3-EE23-E06C-E050-BB89AD4321A6","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D5FC-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D606-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D610-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Clonazepam","valueDescription":"Clonazepam","ValueMeaning":{"publicId":"2577827","version":"1","preferredName":"Clonazepam","longName":"2577827","preferredDefinition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clonazepam","conceptCode":"C28935","definition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D61A-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Diazepam","valueDescription":"Diazepam","ValueMeaning":{"publicId":"2576102","version":"1","preferredName":"Diazepam","longName":"2576102","preferredDefinition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diazepam","conceptCode":"C28982","definition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F653-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"COOPERM","dateModified":"2019-08-05","changeDescription":"Added definition to concept. mc 8/5/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D624-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Lorazepam","valueDescription":"Lorazepam","ValueMeaning":{"publicId":"2578244","version":"1","preferredName":"Lorazepam","longName":"2578244","preferredDefinition":"An anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorazepam","conceptCode":"C619","definition":"A benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, a facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D62E-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Metoclopramide","valueDescription":"Metoclopramide","ValueMeaning":{"publicId":"6261218","version":"1","preferredName":"Metoclopramide","longName":"6261218","preferredDefinition":"A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoclopramide","conceptCode":"C62046","definition":"A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B50088C-AB9A-295D-E053-F662850AD2BF","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D638-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Promethazine","valueDescription":"Promethazine","ValueMeaning":{"publicId":"7460891","version":"1","preferredName":"Promethazine","longName":"7460891","preferredDefinition":"A phenothiazine derivative with antiemetic and antihistaminic properties. Promethazine antagonizes the central and peripheral effects of histamine mediated by histamine H1 receptors. The effects include bronchoconstriction, vasodilation and spasmodic contractions of gastrointestinal smooth muscle. In addition, this agent binds to muscarinic receptors, resulting in anticholinergic and antiemetic activities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Promethazine","conceptCode":"C779","definition":"A phenothiazine derivative with antiemetic and antihistaminic properties. Promethazine antagonizes the central and peripheral effects of histamine mediated by histamine H1 receptors. The effects include bronchoconstriction, vasodilation and spasmodic contractions of gastrointestinal smooth muscle. In addition, this agent binds to muscarinic receptors, resulting in anticholinergic and antiemetic activities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D645-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D65E-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Diphenhydramine","valueDescription":"Diphenhydramine","ValueMeaning":{"publicId":"6261220","version":"1","preferredName":"Diphenhydramine","longName":"6261220","preferredDefinition":"A first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphenhydramine","conceptCode":"C61728","definition":"A first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B50088C-ABE9-295D-E053-F662850AD2BF","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D668-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Dextromethorphan","valueDescription":"Dextromethorphan","ValueMeaning":{"publicId":"7460893","version":"1","preferredName":"Dextromethorphan","longName":"7460893","preferredDefinition":"A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dextromethorphan","conceptCode":"C62022","definition":"A synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D675-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D68E-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Ketamine","valueDescription":"Ketamine","ValueMeaning":{"publicId":"5212051","version":"1","preferredName":"Ketamine","longName":"5212051","preferredDefinition":"A cyclohexanone derivative with analgesic and anesthetic properties. Although its mechanism of action is not well understood, ketamine appears exerts complex pharmacological actions including inhibition of biogenic amine uptake, binding to opioid receptors, and inhibition of N-methyl D-aspartate (NMDA) receptors. Because of the involvement of spinal NMDA receptors in the process of central sensitization, this agent may reduce pain perception and induce sedation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ketamine","conceptCode":"C61797","definition":"A cyclohexanone derivative with analgesic and anesthetic properties. Although its mechanism of action is not well understood, ketamine appears exerts complex pharmacological actions including inhibition of biogenic amine uptake, binding to opioid receptors, and inhibition of N-methyl D-aspartate (NMDA) receptors. Because of the involvement of spinal NMDA receptors in the process of central sensitization, this agent may reduce pain perception and induce sedation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FD7CF95-948C-38AC-E050-BB89AD436C35","latestVersionIndicator":"Yes","beginDate":"2016-04-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D698-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Amantadine","valueDescription":"Amantadine","ValueMeaning":{"publicId":"5633397","version":"1","preferredName":"Amantadine","longName":"5633397","preferredDefinition":"A synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amantadine","conceptCode":"C61632","definition":"A synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. Amantadine appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. Amantadine exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46EDA67D-D7C3-41DC-E053-F662850A0513","latestVersionIndicator":"Yes","beginDate":"2017-01-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6A2-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Quinidine","valueDescription":"Quinidine","ValueMeaning":{"publicId":"7460895","version":"1","preferredName":"Quinidine","longName":"7460895","preferredDefinition":"An alkaloid extracted from the bark of the Cinchona tree with class 1A antiarrhythmic and antimalarial effects. Quinidine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the sodium influx required for the initiation and conduction of impulses resulting in an increase of the threshold for excitation and decreased depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased conduction velocity of nerve impulses. Quinidine exerts its antimalarial activity by acting primarily as an intra-erythrocytic schizonticide through association with the heme polymer (hemazoin) in the acidic food vacuole of the parasite thereby preventing further polymerization by heme polymerase enzyme. This results in accumulation of toxic heme and death of the parasite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Quinidine","conceptCode":"C793","definition":"An alkaloid extracted from the bark of the Cinchona tree with class 1A antiarrhythmic and antimalarial effects. Quinidine stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting the sodium influx required for the initiation and conduction of impulses resulting in an increase of the threshold for excitation and decreased depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased conduction velocity of nerve impulses. Quinidine exerts its antimalarial activity by acting primarily as an intra-erythrocytic schizonticide through association with the heme polymer (hemazoin) in the acidic food vacuole of the parasite thereby preventing further polymerization by heme polymerase enzyme. This results in accumulation of toxic heme and death of the parasite.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D6AF-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6C8-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Nicotine","valueDescription":"Nicotine","ValueMeaning":{"publicId":"3636146","version":"1","preferredName":"Nicotine","longName":"3636146","preferredDefinition":"An addictive CNS stimulant found in the tobacco plant that causes either ganglionic stimulation by depolarization in low doses or ganglionic blockage in high doses. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nicotine","conceptCode":"C691","definition":"A plant alkaloid, found in the tobacco plant, and addictive central nervous system (CNS) stimulant that causes either ganglionic stimulation in low doses or ganglionic blockage in high doses. Nicotine acts as an agonist at the nicotinic cholinergic receptors in the autonomic ganglia, at neuromuscular junctions, and in the adrenal medulla and the brain. Nicotine's CNS-stimulating activities may be mediated through the release of several neurotransmitters, including acetylcholine, beta-endorphin, dopamine, norepinephrine, serotonin, and ACTH. As a result, peripheral vasoconstriction, tachycardia, and elevated blood pressure may be observed with nicotine intake. This agent may also stimulate the chemoreceptor trigger zone, thereby inducing nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFFAAB3F-4ACD-D525-E040-BB89AD433EAD","latestVersionIndicator":"Yes","beginDate":"2012-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-12-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6D2-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Hydrochlorothiazide","valueDescription":"Hydrochlorothiazide","ValueMeaning":{"publicId":"3775356","version":"1","preferredName":"Hydrochlorothiazide","longName":"3775356","preferredDefinition":"The hydrogenated derivative of chlorothiazide, a thiazide diuretic with antihypertensive and anti-urolithic effects. This agent binds to the electroneutral Na-K-Cl cotransporter (NKCC) and thereby impairs Na+, K+ and Cl- reabsorption on the luminal membrane of the early segment in the distal convoluted tubule in the kidney. This leads to an increase in urinary excretion of sodium, chloride, potassium, bicarbonate and water subsequently reducing plasma and extracellular fluid volume leading to a reduction in blood pressure. Hydrochlorothiazide also decreases urinary calcium and uric acid excretion by direct action on the distal tubule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydrochlorothiazide","conceptCode":"C29098","definition":"A short acting thiazide diuretic. Hydrochlorothiazide (HCTZ) is widely used to treat hypertension and edema. This agent's metabolite appears to preferentially bind to and accumulate in red blood cells. This agent is primarily excreted by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6B3ED1-9E4E-50C6-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-06-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6DC-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Famotidine","valueDescription":"Famotidine","ValueMeaning":{"publicId":"2576843","version":"1","preferredName":"Famotidine","longName":"2576843v1.00","preferredDefinition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famotidine","conceptCode":"C29045","definition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F938-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6E6-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Ranitidine","valueDescription":"Ranitidine","ValueMeaning":{"publicId":"5211127","version":"1","preferredName":"Ranitidine","longName":"5211127","preferredDefinition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ranitidine","conceptCode":"C29412","definition":"A member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2FC9BDDD-321C-501F-E050-BB89AD434E5A","latestVersionIndicator":"Yes","beginDate":"2016-04-05","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2016-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6F0-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Cimetidine","valueDescription":"Cimetidine","ValueMeaning":{"publicId":"2577816","version":"1","preferredName":"Cimetidine","longName":"2577816","preferredDefinition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cimetidine","conceptCode":"C374","definition":"A histamine H(2)-receptor antagonist.  Enhancing anti-tumor cell-mediated responses, cimetidine blocks histamine's ability to stimulate suppressor T lymphocyte activity and to inhibit natural killer (NK) cell activity and interleukin-2 production.  Cimetidine also may inhibit tumor growth by suppressing histamine's growth-factor activity and blocking histamine-induced stimulation of vascular endothelial growth factor (VEGF), a pro-angiogenic growth factor. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D6FA-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Trimethoprim","valueDescription":"Trimethoprim","ValueMeaning":{"publicId":"3874338","version":"1","preferredName":"Trimethoprim","longName":"3874338","preferredDefinition":"A synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trimethoprim","conceptCode":"C908","definition":"A synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E591CA67-357B-9D51-E040-BB89AD4371CB","latestVersionIndicator":"Yes","beginDate":"2013-09-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D704-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Sulfamethoxazole","valueDescription":"Sulfamethoxazole","ValueMeaning":{"publicId":"7460897","version":"1","preferredName":"Sulfamethoxazole","longName":"7460897","preferredDefinition":"A sulfonamide bacteriostatic antibiotic that is most commonly used in combination with trimethoprim as the drug Bactrim. Sulfamethoxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulfamethoxazole","conceptCode":"C47737","definition":"A sulfonamide bacteriostatic antibiotic that is most commonly used in combination with trimethoprim as the drug Bactrim. Sulfamethoxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D711-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D72A-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Sodium bicarbonate","valueDescription":"Sodium Bicarbonate","ValueMeaning":{"publicId":"7460898","version":"1","preferredName":"Sodium Bicarbonate","longName":"7460898","preferredDefinition":"The monosodium salt of carbonic acid with alkalinizing and electrolyte replacement properties. Upon dissociation, sodium bicarbonate forms sodium and bicarbonate ions. Ion formation increases plasma bicarbonate and buffers excess hydrogen ion concentration, resulting in raised blood pH.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Bicarbonate","conceptCode":"C29457","definition":"The monosodium salt of carbonic acid with alkalinizing and electrolyte replacement properties. Upon dissociation, sodium bicarbonate forms sodium and bicarbonate ions. Ion formation increases plasma bicarbonate and buffers excess hydrogen ion concentration, resulting in raised blood pH.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D734-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D74D-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Methazolamide","valueDescription":"Methazolamide","ValueMeaning":{"publicId":"7460900","version":"1","preferredName":"Methazolamide","longName":"7460900","preferredDefinition":"A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methazolamide","conceptCode":"C61318","definition":"A sulfonamide derivate and carbonic anhydrase inhibitor with potential antineoplastic activity. Methazolamide inhibits tumor-associated carbonic anhydrase IX (CAIX), which may result in increased cell death in hypoxic tumors. As a hypoxia-inducible transmembrane glycoprotein, CAIX catalyzes the rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions, helping to maintain acidification of the tumor microenvironment and enhance resistance to cytotoxic therapy in some hypoxic tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D75A-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D773-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Dichlorphenamide","valueDescription":"Dichlorphenamide","ValueMeaning":{"publicId":"7460902","version":"1","preferredName":"Dichlorphenamide","longName":"7460902","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dichlorphenamide","conceptCode":"C65376","definition":"No Value Exists","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D780-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D799-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Acetazolamide","valueDescription":"Acetazolamide","ValueMeaning":{"publicId":"4723861","version":"1","preferredName":"Acetazolamide","longName":"4723861","preferredDefinition":"A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal tube of the kidney, the eye, and glial cells. Inhibition of this enzyme in the kidney prevents excretion of hydrogen, leading to increased bicarbonate and cation excretion and increased urinary volume, which results in an alkaline diuresis. Acetazolamide reduces the concentration of bicarbonate, resulting in a decreased synthesis of aqueous humor in the eye, thereby lowering intraocular pressure. Although its mechanism of action is unknown, acetazolamide has anti-convulsant properties resulting from indirect effects secondary to metabolic acidosis or direct effects on neuronal transmission. Acetazolamide also produces respiratory stimulant effects in response to changes to both carbon dioxide and oxygen tension levels within the lungs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetazolamide","conceptCode":"C28809","definition":"A sulfonamide derivative with diuretic, antiglaucoma, and anticonvulsant properties. Acetazolamide is a non-competitive inhibitor of carbonic anhydrase, an enzyme found in cells in the proximal tube of the kidney, the eye, and glial cells. Inhibition of this enzyme in the kidney prevents excretion of hydrogen, leading to increased bicarbonate and cation excretion and increased urinary volume, which results in an alkaline diuresis. Acetazolamide reduces the concentration of bicarbonate, resulting in a decreased synthesis of aqueous humor in the eye, thereby lowering intraocular pressure. Although its mechanism of action is unknown, acetazolamide has anti-convulsant properties resulting from indirect effects secondary to metabolic acidosis or direct effects on neuronal transmission. Acetazolamide also produces respiratory stimulant effects in response to changes to both carbon dioxide and oxygen tension levels within the lungs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FDC9539-B1F4-CB07-E050-BB89AD436926","latestVersionIndicator":"Yes","beginDate":"2015-02-24","endDate":null,"createdBy":"TSANE","dateCreated":"2015-02-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1047D74-D7AD-632D-E053-4EBD850AB0BF","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","deletedIndicator":"No"},{"value":"Prednisone or Prednisolone, Methylprednisolone","valueDescription":null,"ValueMeaning":{"publicId":"12103266","version":"1","preferredName":"Prednisone Or Prednisolone Methylprednisolone","longName":"12103266v1.00","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)_A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC53F43-2FFF-73D0-E053-731AD00AD6D6","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDC53F43-3000-73D0-E053-731AD00AD6D6","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","deletedIndicator":"No"},{"value":"Glucocorticosteroid, Topical","valueDescription":null,"ValueMeaning":{"publicId":"13267505","version":"1","preferredName":"Topical Glucocorticoid","longName":"13267505v1.00","preferredDefinition":"On the surface of the body._A corticosteroid that supports a variety of cardiovascular, metabolic, immunologic, and homeostatic functions, and which binds specifically to the glucocorticoid receptor (GR; NR3C1). Glucocorticoid binding to GR leads to the transportation of the activated receptor-glucocorticoid complex to the nucleus, after which it binds to glucocorticoid response elements (GRE) and regulates the expression of GR-responsive genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical","conceptCode":"C13344","definition":"On the surface of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Glucocorticoid","conceptCode":"C2323","definition":"A corticosteroid that supports a variety of cardiovascular, metabolic, immunologic, and homeostatic functions, and which binds specifically to the glucocorticoid receptor (GR; NR3C1). Glucocorticoid binding to GR leads to the transportation of the activated receptor-glucocorticoid complex to the nucleus, after which it binds to glucocorticoid response elements (GRE) and regulates the expression of GR-responsive genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F809FFF8-D754-5775-E053-731AD00AED76","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F809FFF8-D756-5775-E053-731AD00AED76","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Glucocorticosteroid, Systemic","valueDescription":null,"ValueMeaning":{"publicId":"13267506","version":"1","preferredName":"Systemic Therapy Glucocorticoid","longName":"13267506v1.00","preferredDefinition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body._A corticosteroid that supports a variety of cardiovascular, metabolic, immunologic, and homeostatic functions, and which binds specifically to the glucocorticoid receptor (GR; NR3C1). Glucocorticoid binding to GR leads to the transportation of the activated receptor-glucocorticoid complex to the nucleus, after which it binds to glucocorticoid response elements (GRE) and regulates the expression of GR-responsive genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Glucocorticoid","conceptCode":"C2323","definition":"A corticosteroid that supports a variety of cardiovascular, metabolic, immunologic, and homeostatic functions, and which binds specifically to the glucocorticoid receptor (GR; NR3C1). Glucocorticoid binding to GR leads to the transportation of the activated receptor-glucocorticoid complex to the nucleus, after which it binds to glucocorticoid response elements (GRE) and regulates the expression of GR-responsive genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F809FFF8-D755-5775-E053-731AD00AED76","latestVersionIndicator":"Yes","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F809FFF8-D757-5775-E053-731AD00AED76","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"IVIG","valueDescription":null,"ValueMeaning":{"publicId":"6051439","version":"1","preferredName":"Intravenous Immunoglobulin Therapy","longName":"6051439","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62E6E09D-AF1C-7E3A-E053-F662850A049D","latestVersionIndicator":"Yes","beginDate":"2018-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-16","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F809FFF8-D758-5775-E053-731AD00AED76","beginDate":"2023-03-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-03-29","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":null,"ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B89-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":null,"ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8A-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":null,"ValueMeaning":{"publicId":"2744954","version":"1","preferredName":"Doxorubicin","longName":"2744954","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-8077-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8B-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":null,"ValueMeaning":{"publicId":"5127394","version":"1","preferredName":"Cyclophosphamide","longName":"5127394","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F9F9-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8C-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":null,"ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8D-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":null,"ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8E-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Bleomycin","valueDescription":null,"ValueMeaning":{"publicId":"2739540","version":"1","preferredName":"Bleomycin","longName":"2739540","preferredDefinition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBF7-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B8F-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Vincristine","valueDescription":null,"ValueMeaning":{"publicId":"3380295","version":"1","preferredName":"Vincristine","longName":"3380295","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A54A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B90-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Dacarbazine","valueDescription":null,"ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F836A5AA-5B91-7F58-E053-731AD00A5531","beginDate":"2023-03-31","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-03-31","modifiedBy":"MMADDINENI","dateModified":"2023-03-31","deletedIndicator":"No"},{"value":"Mycophenolate mofetil","valueDescription":null,"ValueMeaning":{"publicId":"5511068","version":"1","preferredName":"Mycophenolate Mofetil (MMF)","longName":"5511068v1.00","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB2EF73-1A77-33B0-E053-F662850AB0D7","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"DAVISJ","dateCreated":"2016-10-12","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA81-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Azathioprine","valueDescription":null,"ValueMeaning":{"publicId":"3128751","version":"1","preferredName":"Azathioprine","longName":"3128751","preferredDefinition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azathioprine","conceptCode":"C290","definition":"A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DF1D25C-1F3C-C451-E040-BB89AD4301E4","latestVersionIndicator":"Yes","beginDate":"2010-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA82-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Plasmapheresis","valueDescription":null,"ValueMeaning":{"publicId":"6159897","version":"1","preferredName":"Plasmapheresis","longName":"6159897","preferredDefinition":"The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8BE-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA83-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":null,"ValueMeaning":{"publicId":"5678505","version":"1","preferredName":"Anti-CD20 (Rituximab)","longName":"5678505v1.00","preferredDefinition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7579-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-10-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA84-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":null,"ValueMeaning":{"publicId":"5678502","version":"1","preferredName":"Anti-TNF (Infliximab, Remicade)","longName":"5678502v1.00","preferredDefinition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-7510-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA85-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Anakinra","valueDescription":null,"ValueMeaning":{"publicId":"7092700","version":"1","preferredName":"Anakinra","longName":"7092700","preferredDefinition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anakinra","conceptCode":"C38717","definition":"A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB90-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA86-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Etanercept","valueDescription":null,"ValueMeaning":{"publicId":"5678501","version":"1","preferredName":"Anti-TNF (Etanercept, Embrel)","longName":"5678501v1.00","preferredDefinition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4974E0F8-74ED-3829-E053-F662850A7949","latestVersionIndicator":"Yes","beginDate":"2017-02-26","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-02-26","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8859145-EA87-3695-E053-731AD00A9790","beginDate":"2023-04-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-04","deletedIndicator":"No"},{"value":"Prednisone or Prednisolone","valueDescription":null,"ValueMeaning":{"publicId":"7850304","version":"1","preferredName":"Prednisone Or Prednisolone","longName":"7850304","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.: An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prednisolone","conceptCode":"C769","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D2B99329-E67F-58B4-E053-4EBD850A7DC2","latestVersionIndicator":"Yes","beginDate":"2021-12-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-12-09","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F899926E-99AD-49EC-E053-731AD00A33D0","beginDate":"2023-04-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-05","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2738661","version":"1","preferredName":"Agent Name","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49E61273-637D-258B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-02","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-04-02","modifiedBy":"ONEDATA","dateModified":"2008-04-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C85ACF-CF07-10C3-E053-4EBD850A23EA","latestVersionIndicator":"Yes","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-05","changeDescription":null,"administrativeNotes":"2023.4.4 PVs added per ticket request CADSR0002164 and CADSR0002265. ak 2023.3.29 PVs added per ticket request CADSR0002214. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the name of the corticosteroid?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Steroid Type:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC52777-61A9-688A-E053-731AD00AB883","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-11-18","modifiedBy":"KUMMEROA","dateModified":"2022-11-28","changeDescription":null,"administrativeNotes":"2022.11.141 Created for ticket request CADSR0001705. 2022.11.28 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}}